Keywords: Pfizer, Debiopharma, Tremelimumab, Melanoma, Research

Pfizer revives development of tremelimumab for advanced melanoma in deal with Debiopharm

Article | 08 January 2010

Print This

Having in April 2008 dropped a late-stage trial of the skin cancer drug, US pharmaceutical leviathan Pfizer has entered into a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in